Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...

The 2025-2026 respiratory viral season is approaching.With it comes the familiar challenge of protecting our most vulnerable ...

In his new book, 'Fair Doses,' epidemiologist Seth Berkley discusses what went right -- and wrong -- with COVID vaccine distribution and whether the world is ready if a new pandemic were to strike.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

IAVI reports its single-dose Lassa fever vaccine is safe and effective, paving way for advanced trials across West Africa.

Q3 2025 Earnings Call Transcript November 6, 2025 Novavax, Inc. misses on earnings expectations. Reported EPS is $-1.24654 ...

India's Coronavirus Vaccine Market offers growth through government-led initiatives, robust manufacturing, and R&D in vaccine ...

Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 ...

Discover Novavax's Q3 2025 earnings: partnership-driven strategy, cost savings, increased revenue outlook, and pipeline progress.

Novavax expects 2026 adjusted revenue between $185 million and $205 million, excluding royalties and sales from its licensing ...

Gaithersburg-based Novavax raised its annual revenue forecast, banking on milestone payments from vaccine supply and licensing deals.